The Potassium Channel, Explained

This is the mechanism behind the most treatable form of neonatal diabetes. It is worth twenty minutes of your attention, because it explains why a tablet can replace injections.

Inside every beta cell — the cells that make insulin — there is a tiny gate in the cell wall called the KATP channel. It lets potassium flow out of the cell.

In normal working, the sequence is this. Sugar arrives in the blood after a feed. The beta cell takes it in and converts it to energy. That energy closes the gate. Closing the gate changes the electrical charge inside the cell, and that change is the signal that makes the cell release its insulin.

So the gate is the switch. Closed gate means insulin released.

In babies with a change in the KCNJ11 or ABCC8 gene, the gate is built slightly wrong and will not close properly. Sugar arrives, energy is produced, but the gate stays open, the electrical signal never happens, and the insulin stays inside the cell — even though the cell is full of it.

Sulfonylureas are a group of tablets, used in diabetes for decades, that close that gate directly by binding to it. They do not need the energy signal. They reach past the fault and shut the gate themselves, and the insulin comes out.

That is the whole story: the insulin was always there, and the medicine restores the switch.

The same gate also exists in muscle and in the brain, which is why some children have neurological features too.